
In today's ACT Brief, we examine why defensible trial data depends on traceability and platform ownership, what CGT site readiness requires as therapy moves to community care, and why data harmonization is AI's primary bottleneck.
Schulman IRB and iMedRIS Data Corporation announce a partnership to provide research organizations with integrated technology, consulting and IRB review services.
Schulman IRB and iMedRIS Data Corporation announce a partnership to provide research organizations with integrated technology, consulting and IRB review services.
Read the full release






